Monte Rosa Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Monte Rosa Therapeutics, Inc. (GLUE) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $8.42 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $8.10.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $7.78, a 38.11% decline year-over-year.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $12.57, a 139.43% increase year-over-year.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $9.65, a 19.28% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $8.09, a 12.45% decline from fiscal 2023.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $9.24, a 21.03% decline from fiscal 2022.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $11.70, a 346.56% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.42 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $8.10 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $9.65 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $7.96 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $8.70 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $8.09 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $7.99 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $7.99 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $7.78 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $9.24 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $8.37 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $8.47 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $12.57 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $11.70 10-K · filed 2023-03-16 | |||
| 2022-09-30 | $12.41 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $11.00 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $5.25 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | $2.62 10-K · filed 2022-03-29 | |||
| 2021-09-30 | $2.19 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $2.19 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |